Immuneering Corporation (Class A) (IMRX) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Immuneering Corporation (Class A) (NASDAQ: IMRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $3.49 (-6.81% 1D, market cap $242.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IMRX ranks #797 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMRX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LFCR (Lifecore Biomedical Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $242.3M) and EVMN (Evommune Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $244.2M). Among the 5-stock peer group, IMRX leads on earnings multiple (N/A) while IMRX leads on capital efficiency (-35.0% ROIC).
Per IMRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001790340), Immuneering Corporation (Class A) generated $166.3M in revenue (-7.3% YoY), -$56.0M in net income, and -$45.5M in free cash flow against $232.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While IMRX currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.23) and Max Pain ($3.66) forces dealer call-delta covering toward $8.90.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Immuneering Corporation (Class A) (IMRX) dropped -6.81% to $3.49, trading at 2% of its 52-week range ($3.38 – $8.48). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Seeking Alpha report covering Immuneering Corporation (Class A) (IMRX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Immuneering Corporation (Class A) (IMRX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Immuneering Corporation (Class A) (IMRX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Immuneering Corporation (Class A) (IMRX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Immuneering Corporation (Class A) (IMRX) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Immuneering Corporation (Class A) (IMRX) market action, institutional positioning, and fundamental catalysts.
- Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N=55) expected in the first half of 2027
- Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer - -MAPKeeper 301 builds on e
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -7.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IMRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IMRX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Immuneering Corporation (Class A) (IMRX) ranks #797 by composite RQD confidence (30/100, grade E) and #547 by equity capitalization ($242.5M). Within this direct 5-issuer industry benchmark cohort, IMRX leads on earnings valuation at N/A trailing P/E, while IMRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LFCR currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with IMRX at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMRX
ACTIVE
Immuneering Corporation (Class A) | E | 30/100 | — | — | -35.0% | -6.81% | $242.5M | Benchmark Subject |
| LFCR Lifecore Biomedical Inc. | C- | 59/100 | — | — | — | -0.16% | $242.3M | /lfcr-vs-imrx → |
| EVMN Evommune Inc. | E | 31/100 | — | — | -35.0% | -10.70% | $244.2M | /evmn-vs-imrx → |
| IFRX InflaRx N.V. | D+ | 54/100 | — | — | — | +6.33% | $244.6M | /ifrx-vs-imrx → |
| CAMP CAMP4 Therapeutics Corporation | E | 26/100 | — | — | -35.0% | -4.67% | $248.5M | /camp-vs-imrx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Immuneering Corporation (Class A) (IMRX) reported GAAP revenue of $166.3M (-7.3% vs. FY2024 revenue of $179.4M , and +1.6% cumulative change since FY2023) , GAAP net income of -$56.0M, operating cash flow of -$45.3M, and free cash flow of -$45.5M (+17.4% YoY). On the balance sheet, IMRX closed FY2025 with $232.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $166.3M | -$56.0M | -$45.3M | -$45.5M | $232.0M | — |
| FY2024 (FY) | 2024-12-31 | $179.4M | -$61.0M | -$55.0M | -$55.1M | $52.7M | — |
| FY2023 (FY) | 2023-12-31 | $163.6M | -$53.5M | -$49.0M | -$49.0M | — | — |
As of 2026-11-03, Immuneering Corporation (Class A) (NASDAQ: IMRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $3.49 (-6.81% 1D, market cap $242.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IMRX ranks #797 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMRX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LFCR (Lifecore Biomedical Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $242.3M) and EVMN (Evommune Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $244.2M). Among the 5-stock peer group, IMRX leads on earnings multiple (N/A) while IMRX leads on capital efficiency (-35.0% ROIC).
Per IMRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001790340), Immuneering Corporation (Class A) generated $166.3M in revenue (-7.3% YoY), -$56.0M in net income, and -$45.5M in free cash flow against $232.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
IMRX last traded at $3.49 (-6.81% on volume of 799,946 shares), positioning the stock -17.49% below its 50-day simple moving average ($4.23) and -27.29% below its 200-day simple moving average ($4.80). Across its 52-week range of $3.38 to $8.48, IMRX sits at the 2.2% percentile with a 14-day RSI of 44.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.8% ($3.08 to $3.90).
Immuneering Corporation (Class A) (IMRX) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.49 (-6.81% 1D, market capitalization $242.5M).
Immuneering Corporation (Class A) trades on NASDAQ under IMRX and is classified in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. It is a Health Care issuer with a market capitalization of $0.3B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Immuneering Corporation (Class A) (IMRX) reported $166.3M in annual revenue (up from $179.4M in FY2024, -7.3% YoY) and -$56.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($163.6M revenue, -$53.5M net income) through FY2025, IMRX scaled operating cash flow to -$45.3M and free cash flow to -$45.5M, backed by $232.0M in total assets against $0 in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), IMRX carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Immuneering Corporation (Class A) (IMRX) • Click "Debate This Headline" to argue it in the Roar Pit below
Seeking Alpha report covering Immuneering Corporation (Class A) (IMRX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Immuneering Corporation (Class A) (IMRX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Immuneering Corporation (Class A) (IMRX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Immuneering Corporation (Class A) (IMRX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Immuneering Corporation (Class A) (IMRX) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Immuneering Corporation (Class A) (IMRX) market action, institutional positioning, and fundamental catalysts.
- Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N=55) expected in the first half of 2027
- Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer - -MAPKeeper 301 builds on e
Picked up a starter position in IMRX in my $100K Virtual Cash book at $3.75. Reported cash rose to $128.6M in FY 2025 from $36.1M in FY 2024, and pancreatic cancer trial patients are reported living longer than projected.. Trading inside a $3.38–$8.48 52-week range with -17.49% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
Both sides have a point here — IMRX's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Negative ROIC of -35%, negative FCF of -$45.5M in FY 2025, and a 3/20 insider conviction pillar show no revenue and weak insider support.. Look at the math on IMRX: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $3.30 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: